Drug therapy and the liver

Several antiretroviral drugs have been associated with liver toxicity, although most have been linked to isolated cases, often in patients with other risk factors such as pre-existing liver disease.

Since the advent of combination antiretroviral therapy, as the mortality rate due to opportunistic infections declined dramatically, liver-related deaths have begun to account for a higher proportion of deaths amongst people with HIV, although this is typically due to hepatitis B and C, rather than drug toxicity.1 2

References

  1. Mocroft A et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 19: 2117-2125, 2005
  2. Salmon-Ceron D et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42: 799-805, 2005
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.